Table of Contents
List of Tables
List of Figures

I. Key Findings

1. Companies Investing in Vancomycin Resistant Enterococcal (VRE) Infection Pipeline include
Number of Companies with Vancomycin Resistant Enterococcal (VRE) Infection projects in pre-clinical Development-
Number of Companies with Vancomycin Resistant Enterococcal (VRE) Infection projects in Clinical Development-
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Companies based in Americas
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Companies based in Europe
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Companies based in Asia Pacific
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Companies based in Rest of the World

2. Pipeline Candidates include
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Agents in pre- clinical/ Discovery stage of Development
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Agents in Clinical Development stage
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Vancomycin Resistant Enterococcal (VRE) Infection Pipeline agents

II. Insights into Vancomycin Resistant Enterococcal (VRE) Infection Pipeline

1. Disease Overview
Introduction to Vancomycin Resistant Enterococcal (VRE) Infection
Symptoms and Causes of Vancomycin Resistant Enterococcal (VRE) Infection
Treatment or Prevention Options for Vancomycin Resistant Enterococcal (VRE) Infection
Other Details

2. Phase wise Pipeline Compounds
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline- Pre- Clinical/ Discovery stage Drugs
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline- Phase 1 stage Drugs
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline- Phase 2 stage Drugs
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline- Phase 3 stage Drugs
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline- Pre-Registration stage Drugs

3. Company wise Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Compounds

4. Vancomycin Resistant Enterococcal (VRE) Infection Pipeline by Mechanism of Action

III. Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Compound Details
- Marinus
- antibiotics for Vancomycin Resistant Enterococci Infections
- AZX1103
- HB1345
- LCB01-0371
- MGB-BP3
- contezolid
- NAI-107
- NAI-603
- Teixobactin
- BDM-I
- OG716
- antibiotic molecule for Vancomycin Resistant Enterococcus Infections
- RBX2660
- SLP-0901
- SLP-0905
- AM 218
- WCK 5222

Drug Details

1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/ License Partner
Orphan Drug / Fast Track/ Designation
Development Phase

2. Drug Overview

3. Mechanism of Action

4. Current Status

5. Clinical Trial Details

IV. Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Company Briefs
- Aphios Corporation
- Arietis Corporation
- AzurRx BioPharma Inc
- Helix BioMedix Inc
- LegoChem Biosciences Inc
- MGB Biopharma Ltd
- MicuRx Pharmaceuticals Inc
- Naicons Srl
- NovoBiotic Pharmaceuticals LLC
- Opal Biosciences Ltd
- Oragenics Inc
- Ovensa Inc
- Rebiotix Inc
- Sealife PHARMA GMBH
- Sinsa Labs Inc
- Wockhardt Ltd

V. Latest News and Developments in Global Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Market
VI. Appendix

1. Publisher's Expertise

2. Research Methodology

3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability

Companies Mentioned:
Aphios Corporation
Arietis Corporation
AzurRx BioPharma Inc
Helix BioMedix Inc
LegoChem Biosciences Inc
MGB Biopharma Ltd
MicuRx Pharmaceuticals Inc
Naicons Srl
NovoBiotic Pharmaceuticals LLC
Opal Biosciences Ltd
Oragenics Inc
Ovensa Inc
Rebiotix Inc
Sealife PHARMA GMBH
Sinsa Labs Inc
Wockhardt Ltd